Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 71722W107 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| BlackRock, Inc. 13G | 5.5% |
7/29/2026
Event 6/30/2026
|
|
|
Millennium Management LLC
13G/A
Amendment 1
|
4.2% |
7/20/2026
Event 6/30/2026
|
|
| Millennium Management LLC | 4.2% | ||
| Millennium Group Management LLC | 4.2% | ||
| Israel A. Englander | 4.2% | ||
|
Millennium Management LLC
13G
|
5.3% |
3/12/2026
Event 3/6/2026
|
|
| Millennium Management LLC | 5.3% | ||
| Millennium Group Management LLC | 5.3% | ||
| Israel A. Englander | 5.3% | ||
|
Millennium Management LLC
13G/A
Amendment 3
|
2.7% |
1/27/2026
Event 12/31/2025
|
|
| Integrated Core Strategies (US) LLC | 1.6% | ||
| Millennium Management LLC | 2.7% | ||
| Millennium Group Management LLC | 2.7% | ||
| Israel A. Englander | 2.7% | ||
|
Frazier Life Sciences Public Fund, L.P.
13D/A
Amendment 11
|
8.6% |
11/4/2025
Event 11/1/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 7.5% | ||
| FHMLSP, L.P. | 7.5% | ||
| FHMLSP, L.L.C. | 7.5% | ||
| Frazier Life Sciences X, L.P. | 0.1% | ||
| FHMLS X, L.P. | 0.1% | ||
| FHMLS X, L.L.C. | 0.1% | ||
| Frazier Life Sciences XI, L.P. | 1.4% | ||
| FHMLS XI, L.P. | 1.4% | ||
| FHMLS XI, L.L.C. | 1.4% | ||
| Frazier Life Sciences IX, L.P. | 8.2% | ||
| FHMLS IX, L.P. | 8.2% | ||
| FHMLS IX, L.L.C. | 8.2% | ||
| Frazier Life Sciences XII, L.P. | 0.4% | ||
| FHMLS XII, L.P. | 0.4% | ||
| FHMLS XII, L.L.C. | 0.4% | ||
| James N. Topper | 8.6% | ||
| Patrick J. Heron | 8.4% | ||
|
Millennium Management LLC
13G/A
Amendment 2
|
7.1% |
11/3/2025
Event 9/30/2025
|
|
| Integrated Core Strategies (US) LLC | 5.8% | ||
| Millennium Management LLC | 7.1% | ||
| Millennium Group Management LLC | 7.1% | ||
| Israel A. Englander | 7.1% | ||
|
Carlyle Group Inc.
13G/A
Amendment 2
|
4.9% |
8/28/2025
Event 8/28/2025
|
|
| Carlyle Group Inc. | 4.9% | ||
| Carlyle Holdings I GP Inc. | 4.9% | ||
| Carlyle Holdings I GP Sub L.L.C. | 4.9% | ||
| Carlyle Holdings I L.P. | 4.9% | ||
| CG Subsidiary Holdings L.L.C. | 4.9% | ||
| TC Group, L.L.C. | 4.9% | ||
| Carlyle Investment Management L.L.C. | 4.9% | ||
| Carlyle Genesis UK LLC | 4.9% | ||
| Abingworth LLP | 4.9% | ||
| Abingworth Bioventures 8 LP | 2.9% | ||
| Abingworth Bioventures VII LP | 2.0% | ||
|
Millennium Management LLC
13G/A
Amendment 1
|
5.9% |
8/25/2025
Event 8/19/2025
|
|
| Integrated Core Strategies (US) LLC | 5.1% | ||
| Millennium Management LLC | 5.9% | ||
| Millennium Group Management LLC | 5.9% | ||
| Israel A. Englander | 5.9% | ||
|
Frazier Life Sciences Public Fund, L.P.
13D/A
Amendment 10
|
8.6% |
8/20/2025
Event 8/18/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 6.0% | ||
| FHMLSP, L.P. | 6.0% | ||
| FHMLSP, L.L.C. | 6.0% | ||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.6% | ||
| FHMLSP Overage, L.P. | 1.6% | ||
| FHMLSP Overage, L.L.C. | 1.6% | ||
| Frazier Life Sciences X, L.P. | 0.1% | ||
| FHMLS X, L.P. | 0.1% | ||
| FHMLS X, L.L.C. | 0.1% | ||
| Frazier Life Sciences XI, L.P. | 1.4% | ||
| FHMLS XI, L.P. | 1.4% | ||
| FHMLS XI, L.L.C. | 1.4% | ||
| Frazier Life Sciences IX, L.P. | 8.2% | ||
| FHMLS IX, L.P. | 8.2% | ||
| FHMLS IX, L.L.C. | 8.2% | ||
| Frazier Life Sciences XII, L.P. | 0.4% | ||
| FHMLS XII, L.P. | 0.4% | ||
| FHMLS XII, L.L.C. | 0.4% | ||
| James N. Topper | 8.6% | ||
| Patrick J. Heron | 8.4% | ||
| Albert Cha | 0% | ||
| James Brush | 0% | ||
| Daniel Estes | 0% | ||
|
Millennium Management LLC
13G
|
5.3% |
8/13/2025
Event 8/11/2025
|
|
| Millennium Management LLC | 5.3% | ||
| Millennium Group Management LLC | 5.3% | ||
| Israel A. Englander | 5.3% | ||
| Jennison Associates LLC 13G/A Amendment 3 | 0% |
6/9/2025
Event 5/31/2025
|
|
| Prudential Financial Inc 13G/A Amendment 2 | 0% |
6/6/2025
Event 5/31/2025
|
|
| Jennison Associates LLC 13G/A Amendment 2 | 0% |
6/4/2025
Event 4/30/2025
|
|
|
Frazier Life Sciences Public Fund, L.P.
13D/A
Amendment 9
|
19.9% |
5/13/2025
Event 5/9/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 8.0% | ||
| FHMLSP, L.P. | 8.0% | ||
| FHMLSP, L.L.C. | 8.0% | ||
| Frazier Life Sciences Public Overage Fund, L.P. | 2.2% | ||
| FHMLSP Overage, L.P. | 2.2% | ||
| FHMLSP Overage, L.L.C. | 2.2% | ||
| Frazier Life Sciences X, L.P. | 0.1% | ||
| FHMLS X, L.P. | 0.1% | ||
| FHMLS X, L.L.C. | 0.1% | ||
| Frazier Life Sciences XI, L.P. | 1.4% | ||
| FHMLS XI, L.P. | 1.4% | ||
| FHMLS XI, L.L.C. | 1.4% | ||
| Frazier Life Sciences IX, L.P. | 8.3% | ||
| FHMLS IX, L.P. | 8.3% | ||
| FHMLS IX, L.L.C. | 8.3% | ||
| Frazier Life Sciences XII, L.P. | 0.3% | ||
| FHMLS XII, L.P. | 0.3% | ||
| FHMLS XII, L.L.C. | 0.3% | ||
| James N. Topper | 19.9% | ||
| Patrick J. Heron | 19.9% | ||
| Albert Cha | 10.1% | ||
| James Brush | 10.1% | ||
| Daniel Estes | 1.7% | ||
| BlackRock, Inc. 13G/A Amendment 1 | 4.6% |
4/24/2025
Event 3/31/2025
|
|
| Prudential Financial Inc 13G/A Amendment 1 | 11.0% |
11/5/2024
Event 10/31/2024
|
|
| Prudential Financial Inc 13G | 9.3% |
11/5/2024
Event 9/30/2024
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 20.8 k | $152 k |
| 2026 Q2 | 172 | 72.6 M | $834 M |
| 2026 Q1 | 181 | 69.1 M | $768 M |
| 2025 Q4 | 180 | 62.0 M | $1.03 B |
| 2025 Q3 | 139 | 62.5 M | $735 M |
| 2025 Q2 | 128 | 57.6 M | $552 M |
| 2025 Q1 | 145 | 64.0 M | $401 M |
| 2024 Q4 | 151 | 66.7 M | $541 M |
| 2024 Q3 | 140 | 72.8 M | $1.31 B |
| 2024 Q2 | 121 | 59.0 M | $608 M |
| 2024 Q1 | 123 | 56.0 M | $595 M |
| 2023 Q4 | 125 | 54.6 M | $508 M |
| 2023 Q3 | 116 | 43.8 M | $453 M |
| 2023 Q2 | 109 | 42.8 M | $613 M |
| 2023 Q1 | 89 | 30.8 M | $220 M |
| 2022 Q4 | 91 | 28.7 M | $322 M |
| 2022 Q3 | 98 | 30.2 M | $334 M |
| 2022 Q2 | 97 | 27.3 M | $237 M |
| 2022 Q1 | 85 | 25.7 M | $349 M |
| 2021 Q4 | 86 | 28.6 M | $562 M |
| 2021 Q3 | 87 | 25.5 M | $820 M |
| 2021 Q2 | 81 | 24.9 M | $844 M |
| 2021 Q1 | 85 | 24.5 M | $919 M |
| 2020 Q4 | 82 | 24.6 M | $816 M |
| 2020 Q3 | 60 | 21.6 M | $794 M |
| 2020 Q2 | 62 | 21.8 M | $719 M |
| 2020 Q1 | 49 | 22.0 M | $566 M |
| 2019 Q4 | 42 | 22.0 M | $682 M |